Gaining access for new therapies is more complex than ever before. Healthcare budgets are under pressure, the pharma market is more competitive, and HTA expectations are evolving rapidly.
That’s why early, integrated planning is critical. Our Market Access experts help you define your strategy, align evidence, and accelerate access in key global markets.
Why choose Clinigen
- Global reach with local insight - projects delivered across US, Europe, LATAM, Asia, and Canada
- Dedicated Market Access team including former policymakers, HTA officials, and clinical experts
- Integrated support across evidence, access, early advice and real-world value planning
Our expertise includes
Evidence and value planning
- HTA and payer landscape mapping
- End-to-end evidence roadmap development
- Risk and impact analysis
- Data source strategy and optimisation
- Clinical guideline alignment
- Central evidence repository
- Patient journey and unmet need insights
Access to market
- Stakeholder mapping and engagement
- Value proposition and messaging alignment
- Market access pathway strategy
- Cross-functional launch planning
- Post-launch value development
- Early access strategy via Concentre™
Early scientific advice
- Simulated scientific advice meetings
- Joint consultation planning (regulatory and HTA)
- Early evidence and protocol optimisation
- Post-launch contingency value planning
Early access programs and real-world data
- Strategic EAP design with value goals in mind
- Real-world data collection embedded in access programs
- Operational delivery aligned to evidence generation
- Post-approval insight and value enhancement
Looking to optimise your market access strategy?
Speak to our experts about building the right evidence, aligning stakeholders and achieving faster access to patients.